Article

High Incidence of Inappropriate Alarms in Patients with Wearable Cardioverter-Defibrillators: Findings from the Swiss WCD Registry

Boldizsar Kovacs 1,* 1, Haran Burri 2, Andres Buehler 1, Sven Reek 3, Christian Sticherling 4, Beat Schaer 4, Andre Linka 5, Peter Ammann 6, Andreas S. Müller 7, Omer Dzemali 8, Richard Kobza 9, Matthias Schindler 1, Laurent Haegeli 10, Kurt Mayer 11, Urs Eriksson 12, Claudia Herrera-Siklody 13, Tobias Reichlin 14, Jan Steffel 1, Ardan M. Saguner 1 and Firat Duru 1,15

1 Department of Cardiology, University Heart Center Zurich, Rämistrasse 100, 8091 Zurich, Switzerland; andres.buehler@usz.ch (A.B.); matthias.schindler@usz.ch (M.S.); jan.steffel@usz.ch (J.S.); ardan.saguner@usz.ch (A.M.S.); firat.duru@usz.ch (F.D.)
2 Department of Cardiology, University of Geneva, 1205 Geneva, Switzerland; Haran.Burri@hcuge.ch
3 Department of Cardiology, University Hospital Basel, 4031 Basel, Switzerland; Christian.Sticherling@usb.ch (C.S.); beat.schaer@usb.ch (B.S.)
4 Department of Cardiology, Cantonal Hospital Winterthur, 8400 Winterthur, Switzerland; andre.linka@ksw.ch
5 Department of Cardiology, Cantonal Hospital St. Gallen, 9007 St. Gallen, Switzerland; peter.ammann@kssg.ch
6 Department of Cardiology, Triemli Hospital Zurich, 8063 Zurich, Switzerland; AndreasStephan.Mueller@triemli.zuerich.ch
7 Department of Cardiology, University Hospital Lausanne, 1011 Lausanne, Switzerland; Omer.Dzemali@triemli.zuerich.ch
8 Department of Cardiology, Cantonal Hospital Lucerne, 6004 Lucerne, Switzerland; richard.kobza@luks.ch
9 Department of Cardiology, Cantonal Hospital Aarau, 5001 Aarau, Switzerland; laurent.haegeli@ksa.ch
10 Department of Cardiology, Canton Hospital Graubünden, 7000 Chur, Switzerland; Kurt.Mayer@ksgr.ch
11 Department of Cardiology, GZO Regional Healthcare Center Wetzikon, 8620 Wetzikon, Switzerland; urs.eriksson@gzo.ch
12 Department of Cardiology, University Hospital Zürich, 1011 Zürich, Switzerland; Claudia.Herrera-Siklody@chuv.ch
13 Department of Cardiology, Inselspital, University Hospital Bern, University of Bern, 3010 Bern, Switzerland; tobias.reichlin@insel.ch
14 Department of Cardiology, Hirslanden Klinik Aarau, 5001 Aarau, Switzerland; Sven.Reek@hirslanden.ch
15 Center for Integrative Human Physiology, University of Zurich, 8006 Zurich, Switzerland

* Correspondence: boldizsarkovacs@usz.ch; Tel.: +41-44-2551515

Abstract: Background: The wearable cardioverter defibrillator (WCD) uses surface electrodes to detect arrhythmia before initiating a treatment sequence. However, it is also prone to inappropriate detection due to artefacts. Objective: The aim of this study is to assess the alarm burden in patients and its impact on clinical outcomes. Methods: Patients from the nationwide Swiss WCD Registry were included. Clinical characteristics and data were obtained from the WCDs. Arrhythmia recordings ≥30 s in length were analysed and categorized as VT/VF, atrial fibrillation (AF), supraventricular tachycardia (SVT) or artefact. Results: A total of 10653 device alarms were documented in 324 of 456 patients (71.1%) over a mean WCD wear-time of 2.0 ± 1.6 months. Episode duration was 30 s or more in 2996 alarms (28.2%). One hundred and eleven (3.7%) were VT/VF episodes. The remaining recordings were inappropriate detections (2736 (91%) due to artefacts; 117 (3.7%) AF; 48 (1.6%) SVT). Two-hundred and seven patients (45%) had three or more alarms per month. Obesity was significantly associated with more or fewer alarms per month (p = 0.01, 27.7% vs. 15.9%). High alarm burden was not associated with a lower average daily wear time (20.8 h vs. 20.7 h, p = 0.078) or a decreased implantable cardioverter defibrillator implantation rate after stopping WCD use (48% vs. 47.3%, p = 0.156). Conclusions: In patients using WCDs, alarms emitted by the device and impending inappropriate shocks were frequent and most commonly caused by artefacts. A high alarm burden was associated with obesity but did not lead to a decreased adherence.
Keywords: wearable cardioverter-defibrillator; alarm; inappropriate therapy; obesity; outcome

1. Introduction

Patients with heart disease who are at high risk for sudden cardiac death (SCD) may be candidates for implantable cardioverter defibrillator (ICD) therapy. ICDs can treat ventricular tachycardia and ventricular fibrillation (VT/VF) by direct current cardioversion or defibrillation, if they are not amenable to overdrive pacing. While ICD therapies can be lifesaving, experiencing a shock while being conscious is often a painful and traumatizing event. Sophisticated device programming with various discrimination and therapeutic algorithms aim to reduce the number of shocks (appropriate or inappropriate), while maintaining the lifesaving capability of these devices [1–4].

The wearable cardioverter defibrillator (WCD) has been introduced for temporary protection against SCD for a limited time period in patients for whom ICD therapy is not indicated or possible. Although several registries have demonstrated that WCDs can prevent SCD [5–10], the VEST trial did not show a reduction in SCD and death from documented ventricular arrhythmia [11]. As a clear benefit from its use is currently lacking, possible harmful effects of WCD use necessitate further scrutiny.

The WCD uses surface electrodes built into the vest with direct skin contact to detect the underlying electrocardiogram of patients [12]. This approach is more prone to artefacts leading to inappropriate arrhythmia detection and shock delivery. A critical feature for the discrimination between artefacts, benign (supraventricular) arrhythmias and VT/VF are algorithms employed by the WCD.

Data on the incidence on alarms emitted by the WCD and their impact on patient outcomes and quality of life is lacking. The aim of this study is to fill this gap by studying the available data from the large Swiss WCD registry.

2. Methods

2.1. Swiss WCD Registry

Characteristics of the Swiss WCD Registry have been reported previously [6]. In short, it is a nationwide, retrospective registry collecting data from 12 participating hospitals of patients, who have a history of WCD use. In this study, we included WCD patients from December 2011 until February 2018.

2.2. WCD Arrhythmia Detection Sequence

Arrhythmia recognition by the WCD (LifeVest, ZOLL, Pittsburgh, Pennsylvania, USA) is based on a proprietary algorithm (TruVectorTM) analysing the heart rate and QRS morphology [12]. Contrary to ICD, the WCD produces a series of warning signals prior to administration of a shock, and patients can press the response buttons to withhold shock application. The emitted alarms include a silent vibration alert, a loud siren alarm, and a voice command warning bystanders of impending shock administration. The duration of an alarm sequence is at least 30 s. A shock can be administered at earliest 30 s after arrhythmia recognition. Every arrhythmia detection leads to the same sequence of alarms (Figure 1). The nominal detection threshold of WCD is programmed as 150 beats per minute (bpm) for VT and 200 bpm for VF for sensitive detection of relevant arrhythmias. The WCD necessitates 5–6 s for arrhythmia recognition, followed by 10 s of arrhythmia confirmation. If VT/VF is confirmed, an alarm sequence is initiated until the patient presses the response button or a shock is administered. Therefore, any detected arrhythmic event leading to an alarm is at least 15 s in duration. All arrhythmic events leading to an alarm are stored on the proprietary LifeVest Network.
2.3. WCD Alarm Events

In this study, any arrhythmia detected by the WCD leading to an actual alarm sequence automatically was termed “alarm” (detected arrhythmia duration at least 15 s). Any arrhythmia detected by the WCD for more than 30 s was deemed potentially clinically relevant and was termed “recording”. All recordings were reviewed for underlying rhythm. Two investigators independently reviewed and adjudicated these recordings as (1) sustained VT (lasting 30 s or more on recording) or VF, (2) non-sustained VT (lasting less than 30 s on recording), (3) atrial fibrillation (AF), (4) supraventricular tachycardia, or (5) artefact. Disagreements were resolved by consensus or arbitration by a third investigator. Bradyarrhythmia events were infrequent and are not included in this analysis.

2.4. Statistical Analysis

A descriptive statistical analysis was performed on the available data set. Categorical variables were reported as frequencies (percentage), continuous variables as means (±standard deviation) or as medians (IQR, range). Statistical analysis was performed using chi square, Fisher’s exact test on categorical variables and univariate regression analysis on continuous variables, as appropriate. A two-sided p value < 0.05 was considered statistically significant. All statistical analyses were conducted using R 1.3.1073 (R Foundation for Statistical Computing, Vienna, Austria).

3. Results

The Swiss WCD Registry included data from 456 patients with a mean follow-up of 514 ± 384 days [6]. The mean effective wear-time of WCD (during which patients actually wore the WCD) was 2.0 ± 1.6 months. A total of 10653 alarms were registered during the observed period. Of these, 7657 alarms (71.9%) were triggered by arrhythmia detection shorter than 30 s and, accordingly, deemed clinically irrelevant. The length of detected arrhythmia episodes was 30 s or more in 2996 (28.1%) of these recordings. The mean alarm burden for the total population was 24.4 alarms per month per patient and the median alarm burden was 3 (IQR 0–17). One hundred and thirty-two patients (28.9%) had no alarms, and thus no recordings. Patients who had at least one alarm had a mean number of 34.3 alarms per month (Supplementary Figure S1). Two-hundred and seven patients (45%) had three or more alarms per month. Baseline characteristics, including stratification of <3 vs. ≥3 alarms/month are shown in Table 1.
Table 1. Baseline characteristics of patients in the Swiss WCD Registry.

|                          | <3 Alarms Per Month (n = 249) | ≥3 Alarms Per Month (n = 207) | Total (n = 456) | p Value |
|--------------------------|-------------------------------|-------------------------------|-----------------|---------|
| **Age**                  |                               |                               |                 |         |
|                          | 57.9 (14.0)                   | 56.6 (14.0)                   | 57.3 (14.0)     | 0.325   |
| **Sex**                  |                               |                               |                 |         |
| Female                   | 46 (18.5%)                    | 35 (16.9%)                    | 81 (17.8%)      | 0.663   |
| Male                     | 203 (81.5%)                   | 172 (83.1%)                   | 375 (82.2%)     |         |
| **BMI (kg/m²)**          |                               |                               |                 | 0.01 #  |
| <18                      | 5 (2.0%)                      | 4 (2.0%)                      | 9 (2.0%)        |         |
| 18–29                    | 201 (82.0%)                   | 142 (70.3%)                   | 343 (76.7%)     |         |
| ≥30                      | 39 (15.9%)                    | 56 (27.7%)                    | 95 (21.3%)      |         |
| **LVEF**                 |                               |                               |                 | 0.140   |
|                          | 30.7 (13.3)                   | 32.5 (12.9)                   | 31.5 (13.1)     |         |
| **Indication for WCD**   |                               |                               |                 | 0.113   |
| Low LVEF                 | 96 (38.6%)                    | 56 (27.1%)                    | 152 (33.3%)     |         |
| Recent myocardial infarction | 62 (24.9%)                  | 63 (30.4%)                    | 125 (27.4%)     |         |
| Bridging *               | 30 (12.0%)                    | 39 (18.8%)                    | 69 (15.1%)      |         |
| Recent PCI or CABG with low LVEF | 23 (9.2%)               | 13 (6.3%)                     | 36 (7.9%)       |         |
| VT with normal LVEF      | 18 (7.2%)                     | 17 (8.2%)                     | 35 (7.7%)       |         |
| Percutaneous or surgical valve repair with low EF | 8 (3.2%)               | 5 (2.4%)                      | 13 (2.9%)       |         |
| Syncope                  | 3 (1.2%)                      | 3 (1.4%)                      | 6 (1.3%)        |         |
| Other                    | 9 (3.6%)                      | 11 (5.3%)                     | 20 (4.4%)       |         |
| **Underlying heart disease** |                          |                               |                 | 0.358   |
| Ischemic cardiomyopathy without coronary dissection | 140 (56.2%)                 | 133 (64.3%)                   | 273 (59.9%)     |         |
| Non-ischemic cardiomyopathy | 65 (26.1%)                  | 43 (20.8%)                    | 108 (23.7%)     |         |
| Valvular                 | 15 (6.0%)                     | 8 (3.9%)                      | 23 (5.0%)       |         |
| Myocarditis              | 5 (2.0%)                      | 5 (2.4%)                      | 10 (2.2%)       |         |
| Channelopathy            | 7 (2.8%)                      | 2 (1.0%)                      | 9 (2.0%)        |         |
| Congenital               | 2 (0.8%)                      | 5 (2.4%)                      | 7 (1.5%)        |         |
| Ischemic cardiomyopathy with coronary dissection | 1 (0.4%)               | 1 (0.5%)                      | 2 (0.4%)        |         |
| Other                    | 14 (5.6%)                     | 10 (4.8%)                     | 24 (5.3%)       |         |
| **Medical therapy**      |                               |                               |                 |         |
| Betablocker              | 227 (91.2%)                   | 187 (90.3%)                   | 414 (90.8%)     | 0.761   |
| ACEi, ARB or neprilysin inhibitor | 219 (88.0%)               | 181 (87.4%)                   | 400 (87.7%)     | 0.868   |
| Aldosterone antagonist   | 147 (59.0%)                   | 132 (63.8%)                   | 279 (61.2%)     | 0.302   |
| Amiodarone               | 43 (17.3%)                    | 37 (17.9%)                    | 80 (17.5%)      | 0.866   |
| Atrial fibrillation      | 59 (23.7%)                    | 49 (23.7%)                    | 108 (23.7%)     | 0.995   |
| Atrial flutter           | 19 (7.6%)                     | 16 (7.7%)                     | 35 (7.7%)       | 0.968   |
| Other supraventricular tachycardia | 8 (3.2%)               | 3 (1.4%)                      | 11 (2.4%)       | 0.222   |

Data are displayed according to number of alarms emitted by the WCD per month. Mean (SD) and number (%). Statistical analysis was performed with chi square, fisher’s exact test or univariate regression analysis, as appropriate. * Bridging until ICD-reimplantation, until primary ICD implantation or until heart transplant. # Statistically significant finding. Abbreviations: ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin II receptor antagonist; BMI = body mass index; CABG = coronary artery bypass graft; LVEF = left ventricular ejection fraction; PCI = percutaneous coronary intervention; VT = ventricular tachycardia.

3.1. Analysed Recordings

Analysis of all recordings (n = 2996) revealed that 111 (3.7%, 1% of all alarms) were correctly identified as VT/VF episodes. These consisted of 89 sustained episodes (80.2%), 17 episodes with shock delivery (15.3%), and 5 non-sustained episodes (4.5%). Of note, the non-sustained episodes were likely detected, in part, due to artefact, as the actual arrhythmia duration was below 30 s. The remaining recordings were either artefacts (2736, 91%), AF (117, 3.7%) or supraventricular tachycardia (48, 1.6%) (Figure 2). There were no inappropriate shocks detected during the observed time period.
3.1. Analysed Recordings

Analysis of all recordings \( n = 2996 \) revealed that 111 \( (3.7\%, 1\% \text{ of all alarms}) \) were correctly identified as VT/VF episodes. These consisted of 89 sustained episodes \( (80.2\%) \), 17 episodes with shock delivery \( (15.3\%) \), and 5 non-sustained episodes \( (4.5\%) \). Of note, the non-sustained episodes were likely detected, in part, due to artefact, as the actual arrhythmia duration was below 30 s. The remaining recordings were either artefacts \( (2736, 91\%) \), AF \( (117, 3.7\%) \) or supraventricular tachycardia \( (48, 1.6\%) \) (Figure 2). There were no inappropriate shocks detected during the observed time period.

3.2. Variables Associated with High Alarm Burden

Patients with three or more alarms per month had a significantly higher BMI. This difference was mainly due to the higher number of patients with \( \geq 3 \) alarms per months who were obese as per the World Health Organisation (WHO) definition (Table 1). This finding persisted in regression analysis adjusted for age, sex, underlying heart disease, indication for WCD and total number of days of WCD use. The mean BMI of patients without any alarms was 25.7 kg/m\(^2\) \( (\pm 5.3) \), compared to 27 kg/m\(^2\) \( (\pm 6.1) \) in patients with at least one alarm. Association of a higher alarm burden due to analysed artefact recordings is shown in Supplementary Table S1.

Significantly more patients with a clinical diagnosis of AF had at least one episode of recorded AF, as expected \( (63.6\% \text{ vs. } 22.7\%, p = 0.002) \). On the other hand, no patient with a clinical diagnosis of other supraventricular tachycardia had an episode of supraventricular tachycardia recorded by the WCD.

3.3. Impact of Alarms on Stopping WCD Use and ICD Implantation

WCD use was discontinued most commonly due to ICD implantation \( (212, 47.6\%) \) (Table 2). In the remaining patients, the majority \( (183, 75.6\%) \) had no further indication for ICD. Comfort issues or patient choice were reasons for stopping WCD use in 45 patients \( (9.9\%) \). Of note, \( \geq 1 \) alarm per day did not lead to a significantly higher rate of stopping the WCD for comfort reasons (Table 3).

A higher rate of WCD alarms per month, did not have a significant impact on ICD implantation rates. In fact, the ICD implantation rate was marginally higher in patients with three or more alarms per month (Table 2). On the other hand, patients with at least one episode of recorded VT/VF had a significantly higher ICD implantation rate after stopping WCD use \( (85.7\% \text{ vs. } 45.8\%, p < 0.001) \). These patients also had a trend towards a higher rate of appropriate ICD therapies \( (22.2\% \text{ vs. } 9.2\%, p = 0.081) \) during follow-up (Supplementary Table S2).

Figure 2. Categories of analysed recordings \( n = 2996 \), VT = ventricular tachycardia.
Table 2. WCD wear data and outcomes.

| Reason for stopping WCD use          | <3 Alarms Per Month (n = 249) | ≥3 Alarms Per Month (n = 207) | Total (n = 456) | p Value |
|-------------------------------------|-------------------------------|------------------------------|-----------------|---------|
| Average wear hours per day          | 20.7 (4.4)                    | 20.8 (3.8)                   | 20.8 (4.2)      | 0.785   |
| Reason for stopping WCD use         |                               |                              |                 |         |
| ICD implantation                    | 106 (42.6%)                   | 90 (43.5%)                   | 196 (43.0%)     | 0.610   |
| Normalized arrhythmic risk          | 91 (36.5%)                    | 76 (36.7%)                   | 167 (36.6%)     |         |
| Comfort issue or patient choice     | 22 (8.8%)                     | 23 (11.1%)                   | 45 (9.9%)       |         |
| LVEF after WCD use                  | 30 (12.0%)                    | 18 (8.7%)                    | 48 (10.5%)      |         |
| Device implanted                    |                               |                              |                 |         |
| ICD                                 | 115 (47.3%)                   | 97 (48.0%)                   | 212 (47.6%)     | 0.156   |
| PM                                  | 0 (0.0%)                      | 3 (1.5%)                     | 3 (0.7%)        |         |
| Unknown                             | 128 (52.7%)                   | 102 (50.5%)                  | 230 (51.7%)     |         |
| LVEF after WCD use                  |                               |                              |                 |         |
| ICD                                 | 115 (47.3%)                   | 97 (48.0%)                   | 212 (47.6%)     | 0.454   |
| PM                                  | 0 (0.0%)                      | 3 (1.5%)                     | 3 (0.7%)        |         |
| Unknown                             | 128 (52.7%)                   | 102 (50.5%)                  | 230 (51.7%)     |         |
| Follow-up duration (days)           | 545.4 (383.6)                 | 478.6 (383.5)                | 514.3 (384.1)   | 0.225   |

Table 3. Alarm burden in WCD patients.

| Reason for stopping WCD use          | <1 Alarm Per Day (n = 407) | ≥1 Alarm Per Day (n = 49) | Total (n = 456) | p Value |
|-------------------------------------|----------------------------|---------------------------|-----------------|---------|
| Average wear hours/day              | 20.8 (4.0)                 | 20.0 (5.0)                | 20.8 (4.2)      | 0.161   |
| Reason for stopping WCD use         |                            |                           |                 |         |
| Normalized arrhythmic risk          | 147 (36.1%)                | 20 (40.8%)                | 167 (36.6%)     | 0.521   |
| ICD implantation                    | 173 (42.5%)                | 23 (46.9%)                | 196 (43.0%)     |         |
| Comfort issue or patient choice     | 42 (10.3%)                 | 3 (6.1%)                  | 45 (9.9%)       |         |
| Unknown                             | 45 (11.1%)                 | 3 (6.1%)                  | 48 (10.5%)      |         |
| Reason for not implanting an ICD    |                            |                           |                 | 0.007*  |
| Not indicated                       | 163 (74.8%)                | 20 (83.3%)                | 183 (75.6%)     |         |
| Patient choice                      | 20 (9.2%)                  | 0 (0.0%)                  | 20 (8.3%)       |         |
| Unknown                             | 28 (12.8%)                 | 0 (0.0%)                  | 28 (11.6%)      |         |
| Terminal stadium §                  | 4 (1.8%)                   | 2 (8.3%)                  | 6 (2.5%)        |         |
| Other                               | 3 (1.4%)                   | 2 (8.3%)                  | 5 (2.1%)        |         |

Data are displayed mean (SD) and as number (%). Statistical analysis was performed with chi square, fisher’s exact test or univariate regression analysis, as appropriate. * follow-up duration for patients implanted with an ICD, includes the duration of WCD use and follow-ups in the device clinic. Abbreviations: ICD = implantable cardioverter-defibrillator; LVEF = left ventricular ejection fraction; PM = pacemaker, WCD = wearable cardioverter-defibrillator.

3.4. Patients with Very High Alarm Burden

Forty-nine patients (10.7%) had at least one alarm per day on average emitted by their WCD over the complete wear period. There was a trend towards a higher high alarm burden in men (p = 0.063), whereas other baseline characteristics were comparable between patients with 1 or more alarms per day and those with less frequent alarms. Importantly, the very high number of alarms had neither a significant impact on the reason for stopping the use of the WCD nor on the rate of ICD implantation in these patients (Table 3).
4. Discussion

Several clinically relevant findings deserve to be highlighted from the analysis of our nationwide registry: (1) Almost half of all patients with WCD had at least three alarms emitted per month by their device; (2) a very high alarm burden (at least one alarm per day) was noted in approximately 11% of patients over the complete WCD wear period, most of these being male patients; (3) the higher alarm burden, however, did not lead to a decreased adherence, as determined by average daily wear-times; (4) obesity was significantly associated with a higher alarm burden; and (5) most alarms were due to artefact or rapidly conducted atrial fibrillation.

Alarms have an important role in the mechanism of WCD. Due to limited reliability of surface ECG recordings, a second fail-safe is available. If a VT/VF is detected by the WCD, a series of vibratory and auditory alarms are emitted by the device, and patients can manually abort the delivery of DC, if they are still conscious. In case of ongoing arrhythmia detection, the alarms are deployed repeatedly, which may possibly lead to anxiety and a decreased quality-of-life in these patients.

It has been demonstrated that inappropriate ICD shocks can negatively impact prognosis of patients [3,4]. Therefore, it is also of paramount importance for patients using the WCD, especially in the susceptible early phase of their disease process, to prevent inappropriate delivery of shocks. Here, for the first time, we describe the impact of impending shock alarm burden on clinical outcomes from the database of a large national registry. Other studies have reported common occurrence of inappropriate detection and device alarms, mostly due to artefacts [13–15]. In our cohort, we also report a high number of alarms, most of which were caused by short detected arrhythmic episodes and detection artefacts. It is obvious that such alarms can have a deleterious effect on the quality-of-life of patients and may even impact further adherence to prescribed therapy.

To date, only small retrospective reports on the quality-of-life in patients with WCD use have been published. A study on 123 patients who were eligible for a WCD, depression and anxiety symptoms were common (21% and 52%, respectively), and WCD recipients showed similar changes of depression and anxiety at 6 weeks when compared to non-recipients [16]. Another small study reported a high rate of sleep disturbances (48%), fear of shock (29%), but also feeling of safety (64%) [13]. The authors noted a significantly higher rate of fear of shock in patients with frequent alarms. In our study, the higher alarm burden did not negatively impact the average daily wear-time, the decision to stop WCD use or medication used. Importantly, ICD implantation rate after stopping WCD use was also not significantly affected by higher alarm burden. Although we did not evaluate the impact of alarm burden on objective measures of quality-of-life, we assessed if stopping WCD use was due to discomfort or patient choice. Interestingly, a similar percentage of patients with higher and lower alarm burden chose to terminate WCD use. This suggests that, although a significant number of patients stop WCD use with persisting indication, the alarm burden does not seem to significantly alter this decision. The reason for the lack of detrimental effect of alarm burden on termination of WCD use is unclear. We speculate that the more frequent consultations and care by the ZOLL support team and as a consequence the treating physician may increase adherence in general, including the use of WCD. This has been suggested to have caused the decrease in mortality in the VEST trial despite the lack of significant effect on arrhythmic death [11].

The high rate of inappropriate arrhythmia detection was directly responsible for the high alarm burden in our study. The efficacy of WCD shock delivery and arrhythmia conversion rate in demographics based on age and BMI has already been established [17,18]. However, the varying rate of alarm burden has not been investigated in this context. We found that obese patients were significantly more likely to have a higher alarm burden. A decreased skin-contact of the ECG electrodes and movement of subcutaneous tissue due to the patients’ body constitution may explain this finding. Wan et al. investigated the efficacy of WCD shocks in obese patients. They found a similar conversion rate irrespective of BMI, although the impedance measured by the defibrillator pads directly correlated
to the BMI. Of note, an increased body weight did not increase the rate of inappropriate shocks. However, the higher alarm burden, which we have demonstrated in obese patients in our study, suggests that these patients more frequently need to be alert and manually abort an impending inappropriate shock.

In our study, of all VT/VFs, 80% were sustained episodes, for which patients manually inhibited shock administration, whereas shock delivery occurred in only a small percentage of the patients. The higher rate of sustained VT/VF episodes compared to non-sustained episodes was possibly due to the shorter episodes not being registered by the WCD by default. Although ICD implantation was significantly more frequent in patients with at least one episode of documented VT/VF, 14% of these patients did not later undergo ICD implantation, which was largely due to patients’ choice and terminal patient status. According to current guidelines, ICD implantation is indicated in the presence of hemodynamically relevant VT [19,20]. Data on the prognostic impact of ICD implantation in patients with hemodynamically tolerated VT, such as patients capable of inhibiting of shock administration by the WCD, are lacking from randomized-controlled trials. On the other hand, sustained or non-sustained VT episodes may have prognostic implications in patients with heart failure [4,21]. Indeed, we observed a trend in patients with at least one VT/VF episode recorded by the WCD and subsequent ICD implantation after stopping WCD use, towards a higher prevalence of appropriate ICD therapies shorter time to therapy.

Attention needs to be given to patients with high alarm burdens, and not only to patients with appropriate alarms due to VT/VF episodes. Particular attention is needed for obese patients. Even though we did not detect an increased rate of inappropriate shocks or a decrease in adherence to therapy, the likely psychological effect on patients should not be underestimated. Alarms during the night-time and longer alarms could theoretically induce more stress in WCD patients. Unfortunately, data on the time and duration of individual alarms were not available in our registry. Inquiring the frequency of WCD alarms should be part of routine clinical follow-up and effort should be made to minimize alarm burden due to artefacts (i.e., by refitting the vest of the WCD). Moreover, examining activity levels of patients and correlating them to the alarm burden is a recently emerging possibility by the TRENDS function of the WCD [22,23].

Our study has several limitations. Data on the impact of alarm burden on validated quality of life scores would be of interest but were not available. Furthermore, arrhythmia recordings less than 30 s in length were not systematically analysed.

5. Conclusions

In patients using WCDs, alarms emitted by the device in the form of vibratory and auditory alerts and impending inappropriate shocks were frequent and were most commonly caused by artefacts. A high alarm burden did not lead to a decreased adherence, as determined by average daily wear-times. Obesity was significantly associated with a higher alarm burden.

Supplementary Materials: The following are available online at https://www.mdpi.com/article/10.3390/jcm10173811/s1, Figure S1: Distribution of alarm burden in patients with at least one alarm per month, Table S1: Artefacts in WCD patients, Table S2: Outcome based on VT/VF recordings.

Author Contributions: Conceptualization, B.K., S.R., H.B. and F.D.; methodology, B.K., M.S. and F.D.; software, B.K., M.S.; validation, A.B., M.S.; formal analysis, B.K. and M.S.; investigation, B.K., A.B., H.B., F.D., C.S., B.S., T.R., L.H., U.E., J.S., A.L., P.A., A.S.M., O.D., R.K., K.M., A.M.S.; resources, C.H.-S.; data curation, B.K., M.S.; writing—original draft preparation, B.K.; writing—review and editing, all co-authors.; visualization, B.K., M.S.; supervision, F.D.; project administration, B.K.; funding acquisition, n/a. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.
Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee of the Cantonal Ethics Committee of Zurich (BASEC-Nr. 2017-01044).

Informed Consent Statement: Written informed consent has been obtained from the patient(s) to publish this paper.

Data Availability Statement: Data used in this study can be made available upon reasonable request.

Conflicts of Interest: H.B.: Speaker fees from Abbott, Biotronik, Microport and Medtronic. Institutional grants from Abbott, Biotronik, Boston Scientific, Medtronic, Microport. S.R.: Educational grants from Abbott, Amgen, Bayer, Biotronik, Bristol-Myers Squibb, Daiichi Sankyo, Merck/MSD, Novartis, Sanofi-Aventis, Servier, Speaker fees from ZOLL. C.S.: Consultant and/or speaker fees from Abbott, Biosense Webster, Biotronik, Boston Scientific, Medtronic, Microport and Zoll. Research grants from Biotronik, Medtronic, Boston Scientific. A.S.M.: received fellowship and training support from Biotronik, Boston Scientific, Medtronic, Abbott/St. Jude Medical, and Biosense Webster and speaker and/or consultant honoraria from Biosense Webster, Medtronic, Abbott/St. Jude Medical, AstraZeneca, Daiichi Sankyo, Biotronik, MicroPort; all outside of this work. R.K.: Institutional grants from Abbott, Biosense-Webster, Biotronik, Boston, Medtronic und SiS-Medical. Consultant honoraria from Biosense Webster. L.H. has received institutional grants from Abbott, Abiomed, Amgen, AstraZeneca, Bayer, Biosense Webster, Biotronik, Boston Scientific, Bracco, B. Braun, Daiichi-Sankyo, Edwards, Medtronic, MicroPort, Novartis, Vascular Medical and Zoll. U.E.: received fellowship and training support from Boston Scientific, Medtronic, Abbott/St. Jude Medical, and Biosense Webster. Speaker and/or consultant honoraria from Novartis, AstraZeneca, Daiichi Sankyo, Boehhringer, Menarini, and Biotronik, as well as institutional research grants from MicroPort, Biotronik, Boston scientific; all outside of this work. C.H.S.: Speaker fees from Daiichi Sankyo. T.R.: Consultant and/or speaker fees from Abbott/SJM, Astra Zeneca, Brahms, Bayer, Biosense-Webster, Biotronik, Boston-Scientific, Daiichi Sankyo, Medtronic, Pfizer-BMS and Roche, all for work outside the submitted study. Received support for his institution from Abbott/SJM, Biosense-Webster, Biotronik, Boston-Scientific and Medtronic for work outside the submitted study. J.S.has received consultant and/or speaker fees from Abbott, Amgen, Astra-Zeneca, Bayer, Berlin-Chemie, Biosense Webster, Biotronik, Boehhringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Medscape, Medtronic, Merck/MSD, Novartis, Roche Diagnostics, Pfizer, Portola, Saja, Servier, and WebMD. He reports ownership of CorXL. Steffel has received grant support through his institution from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, Daiichi Sankyo, and Medtronic. A.M.S.: Educational grants through his institution from Abbott, Bayer, Biosense Webster, and Pfizer BMS, and speaker fees from Bayer, Pfizer BMS and Daiichi-Sankyo. F.D.: Institutional grant support from Abbott, Biotronik, Boston Scientific, Medtronic, Biosense Webster, and Zoll. The other authors do not report any conflicts of interest.

References
1. Moss, A.J.; Schuger, C.; Beck, C.A.; Brown, M.W.; Cannom, D.S.; Daubert, J.P.; Estes, N.A.M.; Greenberg, H.; Hall, W.J.; Huang, D.T.; et al. Reduction in Inappropriate Therapy and Mortality through ICD Programming. *N. Engl. J. Med.* 2012, 367, 2275–2283. [CrossRef]
2. Stiles, M.K.; Fauchier, L.; Morillo, C.A.; Wilkoff, B.L. 2019 HRS/EHRA/APHRS/LAHRS focused update to 2015 expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. *J. Arrhythmia* 2019, 35, 485–493. [CrossRef] [PubMed]
3. Poole, J.E.; Johnson, G.W.; Hellkamp, A.S.; Anderson, J.; Callans, D.J.; Raitt, M.H.; Reddy, R.K.; Marchlinski, F.E.; Yee, R.; Guarneri, T.; et al. Prognostic importance of defibrillator shocks in patients with heart failure. *N. Engl. J. Med.* 2008, 359, 1009–1017. [CrossRef] [PubMed]
4. Biton, Y.; Daimme, U.A.; Baman, J.R.; Kutyifa, V.; McNitt, S.; Polonsky, B.; Zareba, W.; Goldenberg, I. Prognostic Importance of Defibrillator-Appropriate Shocks and Antitachycardia Pacing in Patients With Mild Heart Failure. *J. Am. Heart Assoc.* 2019, 8, 1–8. [CrossRef]
5. Masri, A.; Altibi, A.M.; Erqou, S.; Zmaili, M.A.; Saleh, A.; Al-Adham, R.; Ayoub, K.; Baghal, M.; Alkukhun, L.; Barakat, A.F.; et al. Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death. *JACC Clin. Electrophysiol.* 2019, 5, 152–161. [CrossRef] [PubMed]
6. Kovacs, B.; Reek, S.; Sticherling, C.; Schaer, B.; Linka, A.; Ammann, P.; Brenner, R.; Krasniqi, N.; Mueller, A.S.; Dzemali, O.; et al. Use of the wearable cardioverter-defibrillator—The Swiss experience. *Swiss Med. Wkly.* 2020, 1–9. [CrossRef]
7. Wäßnig, N.K.; Günther, M.; Quick, S.; Pfuecke, C.; Rottstädt, F.; Szymkiewicz, S.J.; Ringquist, S.; Strasser, R.H.; Speiser, U. Experience With the Wearable Cardioverter-Defibrillator in Patients at High Risk for Sudden Cardiac Death. *Circulation* 2016, 134, 635–643. [CrossRef]
8. Chung, M.K.; Szymkiewicz, S.J.; Shao, M.; Zishiri, E.; Niebauer, M.J.; Lindsay, B.D.; Tchou, P.J. Aggregate national experience with the wearable cardioverter-defibrillator: Event rates, compliance, and survival. J. Am. Coll. Cardiol. 2010, 56, 194–203. [CrossRef]

9. Ellenbogen, K.A.; Koneru, J.N.; Sharma, P.S.; Deshpande, S.; Wan, C.; Szymkiewicz, S.J. Benefit of the Wearable Cardioverter-Defibrillator in Protecting Patients After Implantable-Cardioverter Defibrillator Explant. JACC Clin. Electrophysiol. 2017, 3, 243–250. [CrossRef] [PubMed]

10. Kutyifa, V.; Moss, A.J.; Klein, H.; Biton, Y.; McNitt, S.; MacKecknie, B.; Zareba, W.; Goldenberg, I. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the Prospective Registry of Patients Using the Wearable Cardioverter Defibrillator (WEARIT-II Registry). Circulation 2015, 132, 1613–1619. [CrossRef]

11. Olgin, J.E.; Fletcher, M.J.; Vittinghoff, E.; Wranicz, J.; Malik, R.; Morin, D.P.; Zweibel, S.; Buxton, A.E.; Elayi, C.S.; Chung, E.H.; et al. Wearable Cardioverter–Defibrillator after Myocardial Infarction. N. Engl. J. Med. 2018, 379, 1205–1215. [CrossRef] [PubMed]

12. Reek, S.; Burri, H.; Roberts, P.R.; Perings, C.; Epstein, A.E.; Klein, H.U.; EHRAScientific Documents Committee (as external, reviewers); Lip, G.; Gorenek, B.; Sticherling, C.; et al. The wearable cardioverter-defibrillator: Current technology and evolving indications. Europace 2017, 19, 335–345. [CrossRef] [PubMed]

13. Lackermair, K.; Schuhmann, C.G.; Kubieniec, M.; Riesinger, L.M.; Klier, I.; Stocker, T.J.; Kääb, S.; Estner, H.L.; Fichtner, S. Impairment of Quality of Life among Patients with Wearable Cardioverter Defibrillator Therapy (LifeVest®): A Preliminary Study. BioMed Res. Int. 2018, 2018, 602894. [CrossRef]

14. Odeneg, T.; Ebner, C.; Mörtl, D.; Keller, H.; Dirninger, A.; Stix, G.; Föger, B.; Grimm, G.; Steinwender, C.; Gebetsberger, F.; et al. Indications for and outcome in patients with the wearable cardioverter-defibrillator in a nurse-based training programme: Results of the Austrian WCD Registry. Eur. J. Cardiovasc. Nurs. 2019, 18, 75–83. [CrossRef] [PubMed]

15. Sinha, A.-M.; Bense, J.; Hohenforst-Schmidt, W. The impact of wearable cardioverter-defibrillator use on long-term decision for implantation of a cardioverter-defibrillator in a semirural acute care hospital. J. Interv. Card. Electrophysiol. 2020. [CrossRef]

16. Weiss, M.; Michels, G.; Eberhardt, F.; Fehske, W.; Winter, S.; Baer, F.; Choi, Y.H.; Albus, C.; Steven, D.; Baldus, S.; et al. Anxiety, depression and quality of life in acute high risk cardiac disease patients eligible for wearable cardioverter defibrillator: Results from the prospective multicenter CRED-registry. PLoS ONE 2019, 14, e0213261.

17. Daimee, U.A.; Vermilye, K.; Moss, A.J.; Goldenberg, I.; Klein, H.U.; McNitt, S.; Zareba, W.; Kutyifa, V. Experience with the wearable cardioverter-defibrillator in older patients: Results from the Prospective Registry of Patients Using the Wearable Cardioverter-Defibrillator. Hear Rhythm 2018, 15, 1379–1386. [CrossRef]

18. Wan, C.; Szymkiewicz, S.J.; Klein, H.U. The impact of body mass index on the wearable cardioverter defibrillator shock efficacy and patient wear time. Am. Heart J. 2017, 186, 111–117. [CrossRef]

19. Priori, S.G.; Blomström-Lundqvist, C.; Mazzanti, A.; Blom, N.; Borggreve, M.; Camm, J.; Elliott, P.M.; Fitzsimons, D.; Hatala, R.; Hindricks, G.; et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the Europe. Eur. Heart J. 2015, 36, 2793–2867. [CrossRef]

20. Al-khatib, S.M.; Ackerman, M.J.; Gillis, A.M.; Bryant, W.J.; Hlatky, M.A.; Callans, D.J.; Granger, C.B.; Curtis, A.B.; Hammill, S.C.; Kay, G.N.; et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Circulation 2017, 72, e91–e220.

21. Doval, H.C.; Nul, D.R.; Grancelli, H.O.; Varini, S.D.; Soifer, S.; Corrado, G.; Dubner, S.; Scapin, O.; Perrone, S.V. Nonsustained Ventricular Tachycardia in Severe Heart Failure. Circulation 1996, 94, 3198–3203. [CrossRef] [PubMed]

22. Tripp, C.; Burch, A.E.; Erath, J.W.; Hain, A.; Sears, S.F. Physical Activity in Adults With Wearable Cardioverter Defibrillators in the Post–Myocardial Infarction Period. J. Cardiopulm. Rehabil. Prev. 2020, 40, 164–166. [CrossRef] [PubMed]

23. Burch, A.E.; D’Souza, B.; Gimbel, J.R.; Rohrer, U.; Masuda, T.; Sears, S.; Scherr, D. Physical activity is reduced prior to ventricular arrhythmias in patients with a wearable cardioverter defibrillator. Clin. Cardiol. 2019, 43, 60–65. [CrossRef] [PubMed]